Background Medicines used in neonates contain different excipients, which may not be safe in this age group. Objective To analyse the frequency at which hospitalised neonates are exposed to harmful excipients (HEs) and to identify substitution possibilities for medicines containing HEs. Materials and methods Retrospective, observational study at a university paediatric hospital from 1 September 2015 till 29 February 2016. All hospitalised neonates who received a prescription for medicines containing an HE were included. Neonates were divided into four groups according to gestational age (<28 weeks; 28 to <32 weeks; 32 to <37 weeks and ≥37 weeks). The following excipients were analysed: parabens, polysorbate 80, propylene glycol, benzoates, saccharin sodium, sorbitol, ethanol and benzalkonium chloride. Excipients were identified from the Summaries of Product Characteristics. Results 296 (102(34.5%) preterm) neonates included in the study received 1472 prescriptions for 106 medicines. The most often used formulations were intravenous (48/106; 45.3%) and oral solid formulations (20; 18.9%). The total number of different excipients was 169. In total, 29/106 (27.4%) medicines contained at least one HE. In total 82/102 (80.4%) preterm and 118/194 (60.8%) term neonates received medications with at least one HE. Substitution was possible for 9/29 (31.0%) HE-containing medicines. Conclusions Use of HEs can be reduced by using HE-free products available on the European market. However, medicine substitution was possible in only a small number of cases. Therefore the main focus should be on information and education of the hospital specialists about HEs used in medicines and their adverse reactions.
A retrospective and observational analysis of harmful excipients in medicines for hospitalised neonates in Latvia
InTROduCTIOn
Despite widespread use of different excipients in medicines for neonates, there is a lack of detailed description of the extent of such use in neonatal medicines. The pharmacokinetics and safety of many of these agents (eg, ethanol, benzoates) are still not well described. 1 2 Although excipients should have limited pharmacological activity, there are an increasing number of adverse reports in paediatric populations. 3 4 This is mainly because pharmacokinetics and pharmacodynamics of excipients in neonates may have different activity than that in adults and therefore might create adverse reactions. [5] [6] [7] For instance, benzyl alcohol may have a fatal toxic syndrome in premature infants. 8 It 'must not be given to premature babies or neonates' and it 'may cause toxic reactions and allergic reactions in infants and children up to 3 years old'. 9 Probably one of the best known cases in this regard is the so-called E-ferol incident. Thirty-eight premature low birth weight (<1500 g) neonates died after the use of intravenous vitamin E preparation. The cause of death was associated with polysorbate 80 used as a solubilising agent in the preparation. 10 11 The main groups of harmful excipients (HEs) are: ► antimicrobial preservatives (benzalkonium chloride, benzoic acid, benzyl alcohol, sodium benzoate and parabens); ► solubilising agents (polysorbate 80); ► solvents (ethanol and propylene glycol); ► sweetening agents (saccharin sodium and sorbitol). Excipients, analysed in our study, were chosen according to the Nellis et al study. 12 The HE effects have been reported in previous publications (Rowe 2009 , 8 EMA 2003, 9 Nellis et al 2015, 12 Lass et al 2012, 13 etc). For instance, polysorbate 80 may cause E-ferol syndrome. Benzalkonium chloride might be ototoxic when applied to an ear. 8 12 13 Benzoic acid may increase the risk of jaundice in newborn babies, hypersensitivity and kernicterus. 9 12 Medicines with benzyl alcohol may result in headache, vomiting, diarrhoea, 8 13 metabolic acidosis, seizures, gasping, 12 13 hypersensitivity, 13 kernicterus
Key messages
What is already known on this subject ► Generally, pharmaceutical excipients have been considered to be pharmacologically inactive and safe. ► Some pharmaceutical excipients have been associated with toxicity in neonates. ► The extent of excipient use in neonatal medicines is still poorly studied. What this study adds ► Hospitalised neonates in Latvia receive medicines containing harmful excipients (HEs). ► The medicines' substitution was possible in only a small number of cases. ► Collaboration between stakeholders at the local and European level is required to solve the different problems associated with substitution. ► The main focus should be on information and education of hospital specialists about HEs and their possible adverse reactions.
and intraventricular haemorrhage. 12 Premature infants may have fatal toxic syndrome. 12 13 Parabens may cause hyperbilirubinaemia, 12 13 hypersensitivity reactions, 8 9 12 13 oestrogenic effects (propylparaben) 12 and delayed-contact dermatitis. 8 Neonates who use medicines with sodium benzoate may have hypersensitivity, kernicterus 12 and contact urticaria. 8 9 13 Propylene glycol may cause skin irritation, 8 9 12 13 central nervous system) depression, cardiovascular adverse events, 8 12 13 hepatic adverse events, respiratory adverse events, 12 13 hyperosmolality, 8 12 lactic acidosis, 8 12 alcohol-like symptoms (oral, parenteral), 9 ototoxicity, seizures and contact dermatitis. 8 Medicines with ethanol may result in lactic acidosis, hypoglycaemia 12 and CNS effects. 12 13 Sorbitol can cause diarrhoea 9 12 and nutrient malabsorption, 12 and saccharin sodium -urticaria and photosensitivity. 12 13 No official guidelines are available advising which excipients should not be used in neonatal medications. There are some general guidelines-for example, 'Excipients in the label and package leaflet of medicinal products for human use' 9 or 'Guideline on the investigation of medicinal products in the term and preterm neonate', 7 and pharmaceutical excipients handbooks describing general safety data. 8 Probably, the European Study of Neonatal Exposure to Excipients (ESNEE) project 14 and the database of 'Safety and Toxicity of Excipients for Paediatrics' 15 will improve this situation. The ESNEE project was created in order to provide information about the safety of excipients in neonatal medicines. The members of the project group have published some valuable articles-for example, a systematic review of excipients safety. 16 There are also articles focused on risk assessment with regard to neonatal excipient exposure 17 or excipients' safety. 18 Some authors have analysed pharmacokinetic of specific excipients-for example, propylene glycol [19] [20] [21] and benzyl alcohol. 22 Despite some recent pan-European 12 23 and local (country) 13 24-27 studies on excipients used in neonates, there is still a lack of studies in this field. Our main aim was to analyse the frequency of using HEs in hospitalised neonates in the Department of Neonatology; and then, to identify possibility of substituting for medicines containing HEs.
MeThOdS
This retrospective observational cohort study was performed at the University Children's Hospital in Riga, Latvia. This is a multispecialty university paediatric hospital with approximately 500 beds. The Department of Neonatology has an intensive care unit (NICU) and a neonatal ward. Hospitalised neonates who received a prescription for medicines containing an HE were included in the study. Most of these patients (all preterm babies) were admitted to the NICU. The study lasted from 1 September 2015 to 29 February 2016. The following information was collected from the patients' medical records by a clinical pharmacist: demographic data (date of birth, gender, gestational age, birth weight), admission and discharge dates, prescribed medicines, dosages and the route of administration. Neonates were divided into four groups according to the gestational age (<28 weeks, called extremely preterm; 28 to <32 weeks, very preterm; 32 to <37 weeks, late preterm and ≥37 weeks, term neonates) 12 28 as the severity and type of complications of preterm infants may be directly proportional to neonatal immaturity and their physiological status. 29 All medicines and food supplements prescribed to hospitalised neonates were analysed, except for blood products, glucose and electrolyte solutions, vaccines, parenteral nutrition products and contrast agents. Each medicine was classified according to the international non-proprietary name, trade name, pharmaceutical dosage form, strength and route of administration.
Identification of excipients
In this study 12 excipients that have been associated with toxicity in neonates 12 were chosen to see if they were included in any of the medicines prescribed. We chose to analyse the same excipients that were investigated in the recent pan-European point prevalence study. 12 These excipients were benzalkonium chloride, benzyl alcohol, benzoic acid, ethanol, ethyl-, methyl-and propylparahydroxybenzoate, polysorbate 80, propylene glycol, saccharin sodium, sodium benzoate and sorbitol. Excipients and the amount of each HE (if available) were identified from their Summaries of Product Characteristics (SPC) and/or the home pages of manufacturers.
Products' substitution analysis
Substitution was determined according to criteria described in the Nellis et al analysis: 'stage 1 -medicines could be substituted with a product with the same active pharmaceutical ingredient and route of administration; stage 2 -stage 1 plus requirement of identical dosage form; stage 3 -stages 1 and 2 plus requirement of identical strength of the active pharmaceutical ingredient. 23 Only those products not containing any harmful excipient were considered for valid substitution in the analysis.
Statistical analysis
The statistical analysis was performed using IBM SPSS Statistics version 20.0 statistical software package (SPSS Inc, USA) and Microsoft Excel programs. Patients' data were analysed using descriptive statistical methods (percentage proportion, mean and SD). Nominal data were described as the quantity (n) and percentage with 95% CI. Categorical data were analysed with χ2 test (2×2 tables). Data with p value <0.05 were regarded as statistically significant. Categorical data were also described as the quantity and percentage proportion.
The study used anonymised data and did not require individual consent from parents. The local ethics committee approved the study's protocol.
ReSulTS
During the period of study 327 neonates were hospitalised. Thirty-one (9.5%) patients (5 late preterm neonates and 26 term neonates) did not receive medicines containing the HE excipients that were being examined and were excluded from the study. The 296 neonates (102 (34.5%) preterm) included in the study received 1472 prescriptions for 106 medicines ( Original article 1.9%), rectal formulations (1; 0.9%) and subcutaneous formulations (1; 0.9%) were rarely used (table 2) .
Information on excipients was available for all 106 medicines. The total number of different excipients was 169. In total, 29/106 (27.4%) medicines contained at least one HE (figure 1). None of these preparations contained benzoic acid and ethylparabens. Parenteral formulations were the most often used. In total, there were 558 (42.0%) parenteral prescriptions, but only seven (17.1%) medicines contained HE (figure 1). These excipients were benzyl alcohol (3; 42.9% formulations), ethanol (2; 28.6%), methylparahydroxybenzoate (3; 42.9%), propylparahydroxybenzoate (2; 28.6%), propylene glycol (3; 42.9%) and sorbitol (1; 14.3%).
The amount of the HEs was not available in the SPC for 13/29 (44.8%) products. The exact amount of benzalkonium chloride was available in 2 out of 7 medicines in the SPC, benzyl alcohol -1 of 4, ethanol -1 of 3, methylparahydroxybenzoate -1 of 8, sodium benzoate -1 of 3, propylene glycol -2 of 4, propylparahydroxybenzoate -1 of 7, saccharin sodium -1 of 4 and sorbitol -2 of 5 medicines. No information was available about the exact amount of polysorbate 80 in all four medicines used during the period of study. Four HEs were found in two products, three HEs in two products, two HEs in eight products, and one HE in 16 products. In total, 82/102 (80.4%) preterm and 118/194 (60.8%) term neonates received medications with at least one HE. Only 5 (17.2%) medicines were licensed for use in neonates (table 3) .
According to Nellis et al 23 first-stage criteria substitution was possible for 9/29 (31.0%) HE-containing medicines. By adding the second and third stages, the possibility of medicines' substitution was reduced to 7/29 (24.1%) and 4/29 (13.8%), respectively (table 3) . For instance, it is possible to substitute ibuprofen oral suspension (contains methyl-and propylparahydroxybenzoate) with ibuprofen tablets that do not contain HEs (first-stage criteria substitution). Also, it is possible to substitute dexpanthenol cream (contains propylene glycol) with dexpanthenol ointment that does not contain HEs (second-stage criteria substitution), and pyridoxine injection 50 mg/mL (contains methylparahydroxybenzoate) with pyridoxine injection 50 mg/mL without HEs (third-stage criteria substitution).
dISCuSSIOn
Our study shows that hospitalised neonates in Latvia receive medicines containing HEs, but medicines' substitution was possible in only a small number of cases. Thus, the main focus should be on providing information and education for hospital specialists about HEs and their possible adverse reactions. The proportion of medicines containing HEs in our study (27.4%) was almost the same as that reported by Nellis et al 12 (31.0%), but lower than in the study published by Lass et al. 13 (68.0%). The difference from the latter study might be explained by differences in methodology (eg, we did not include analysis of medicines potentially containing HEs in our study). The number of neonates receiving at least one HE was also similar to that reported by Nellis et al. 12 Our study shows that the medicines' substitution was possible in only a small number of cases as compared with the study of Nellis et al. 23 This might be because the Latvian market is small.
In accordance with local legislation (Regulations of Minister Cabinet from 31 October 2006 No. 899 'Procedures for the Reimbursement of Expenditures for the Acquisition of Medicinal Products and Medicinal Devices Intended for Out-patient
Medical Treatment'), the cheapest product must be purchased. Another problem is that these 12 HEs are not mentioned in any European regulation or directive and there are only a few recommendations by specialists as to how to avoid using these excipients in neonates. The results from existing studies may not be sufficiently strong to allow purchase of another HE-free product which has a higher price than the product containing HEs.
Collaboration between stakeholders at the local and European level is required to solve the various problems associated with substitution, such as availability of quantitative data of HEs, toxicological assessment of excipients and substitution costs. Unavailability of suitable formulations for paediatric use may lead pharmacists to prepare extemporaneous liquid preparations. Stability data and the safety of excipients are some of the problems that pharmacists must solve before such preparation. 30 Our hospital pharmacists do prepare some oral solutions-for example, phenobarbital solution with SyrSpend SF PH4 (liquid) or caffeine water solution. Phenobarbital solution should not to be used in neonates because the syrup contains sodium benzoate. Caffeine solution does not contain preservatives, and therefore has a very short shelf-life. Some excipients may not be required for some formulations-for example, antimicrobials for parenteral formulations. 12 In our study 46/53 (86.8%) parenteral formulations and 463 parenteral prescriptions (83.0%) had no HEs. These results are similar to the results of Nellis et al. In their study 85% of parenteral prescriptions did not have parabens and benzoates, which means that these preservatives could be avoided. 12 Substitution was not be possible for two medicines (gentamicin and phenobarbital), which are widely used in neonates. According to European Medicines Agency (EMA) guidelines 'inclusion of antimicrobial preservatives in a medicinal product needs special justification. Wherever possible the use of these substances should be avoided, particularly in paediatric formulations'. 31 In our study parenteral medicines contained benzyl alcohol, ethanol, methyl-and propylparahydroxybenzoate, propylene glycol and sorbitol (table 3) . In total, 19 (65.5%) medicines contained antimicrobial preservatives. Sweeteners should be used with caution as they may cause diarrhoea, 9 12 nutrient malabsorption (sorbitol), 12 urticaria and photosensitivity (saccharin sodium). 12 13 Sorbitol may have laxative effect that should be considered along with its osmotic properties and potential effects on bioavailability. 6 In our study 10 patients received sorbitol (whereas in the Nellis et al study, no patients received a sorbitol-containing formulation) and two patients received medications with saccharin sodium. We found no substitution possibilities for the oral medicines that were used in our study which did not contain sweeteners. For one parenteral formulation (clemastine) it was possible to substitute a therapeutic alternative (chloropyramine) that did not contain HEs. Nevertheless, we would need more information about why clemastine was being used before making the substitution. Most of the medicines containing HEs were not licensed for use in neonates (table 3) . Most of them are off-patent drugs and there is probably limited interest by industry in developing 'paediatric friendly' formulations for these active substances, as such research might be expensive and profit small. Also, parents may not agree to their children participating in clinical studies and there might be too few patients to allow comprehensive conclusions to be reached. No information on adverse reactions due to HEs was found in patients' records; possibly, because physicians had not been warned before the study about such a possibility. Additionally, during the study no adverse reactions were identified. Possibly, the usage of HEs did not reach the toxic level. Calculations of HE intakes might be the next step of this research, although this would not be possible in all cases because the exact amounts of HEs used in specific formulations was not contained in all SPC leaflets. Probably not all pharmaceutical companies are interested in sharing the data. Accepted daily intakes have been reported for some excipients-for example, sodium benzoate daily intake should not exceed 10 mg/kg owing to immature metabolic capability. However, information about a safe dose of a specific excipient is not always available-for example, the EMA has no recommendations on a safe dose for propylene glycol. 32 Different doses are mentioned in the EMA's overview of 22 publications.
Original article
We have initiated discussions with the hospital Drug and Therapeutic Committee about the possibility of purchasing HE-free medicines for neonates if such products are available. As a result, local medication registration prices could be reduced for some specific medications for specific patient groups-for example, HE-free formulations for neonates. Perhaps it would be more attractive for pharmaceutical companies to register such medications in countries with small markets. However, collaboration between stakeholders is required to solve the different problems concerning registration of medicines. Meanwhile, the clinical pharmacist has prepared leaflets and local recommendations on the hospital intranet for doctors containing warnings about currently used medicines with HEs. There is also information about the HEs that these products contain and possible adverse reactions. Discussion is continuing with the hospital pharmacy about the possibility of preparing oral solutions without HEs for neonates. The EMA recommends the avoidance of preservatives, antioxidants, etc, and the use of sterile products to eliminate microbial contamination.
lIMITATIOnS
First, the study period was 6 months and it is possible that not all products containing HEs were identified. Therefore, the clinical pharmacist is reviewing the hospital drug formulary in order to identify other medicines with HEs that might be used in neonates. Second, the study analysed only HEs, and not other excipients known as 'potentially HE' (eg, sodium metabisulfite, disodium edetate). Third, not all SPCs had quantitative information on excipients. Therefore, it was not possible to analyse the amount of excipients that neonates received. We agree with Nellis et al 12 15 23 that quantitative information on excipients is needed before considering a switch from one product to another.
COnCluSIOnS
Neonates in Latvia receive a number of HEs. The use of these excipients can be reduced by using HE-free products available on the European market. However, the possibility of reducing use of these excipients in the hospital is limited owing to the lack HE-free formulations available on the local market, as well as local legislation.
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